At present, reduction of Lp(a) in people with FH relies on the use of PCSK9 inhibitors (Bittner et al., 2020; O'Donoghue et al., 2019), noting that niacin is not recommended in European countries. Here, PCSK9 is linked to familial hyperaldosteronism.